Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences is expected to see continued success in the commercial stage and incubation of discovery-stage companies, with key drug candidates in various stages of development and promising data. With a strong portfolio and plans to engage with the FDA in 2H26, the company demonstrates a commitment to providing innovative solutions for patients and potential for future growth. The valuation is supported by discounted risk-adjusted revenue estimates, with risks including regulatory and commercial challenges.

Bears say

Roivant Sciences is facing a potential delay in the launch of its drug therapy, brepocitinib for the treatment of dermatomyositis (DM), as the FDA has assigned a PDUFA date in 2026. This could negatively impact the company's revenue and profitability in the near term. Additionally, the company's development pipeline faces potential challenges and uncertainties, such as the start of Phase 3 studies and the timing of topline data.

ROIV has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 10 analysts, ROIV has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.